Tilos Therapeutics is developing antibody therapeutics specific for LAP, latency-associated peptide of TGFβ. Anti-LAP antibodies effectively reduce tumor growth in mouse cancer models and have the potential to be a powerful new class of therapeutics in the treatment of cancer, as well as fibrosis and autoimmunity.